SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Boxlight Corp. is a technological company, which engages in developing, selling, and providing interactive classroom solutions for the global education market. It also designs, manufactures, and distributes interactive projectors, flat panel displays, touch projectors, touch boards, and MimioTeach through the Boxlight Group and Genesis brands. The company was founded by Herbert Myers and Sloan Myers in 1985 and is headquartered in Duluth, GA.

Boxlight Corporation - Ordinary Shares - Class A

Boxlight Corp

BOXL is trending due to a reported breakout potentially fueled by news of shipping Google EDLA-certified interactive displays. Community discussions revolve around short squeeze potential and high volatility. Some traders point to the company's history of dilution as a reason for caution, while others express optimism for a continued run.

AgriFORCE Growing Systems Ltd. is an agriculture technology company, which engages in the development and utilization of intellectual property (IP) assets for improvement. Its solutions include consulting, air and surface sterilization, and other projects. The company was founded on December 22, 2017 and is headquartered in Vancouver, Canada.

AgriFORCE Growing Systems ltd

AgriFORCE is trending due to news of a potential $550 million fundraising plan led by Anthony Scaramucci to acquire AVAX tokens, with the company potentially shifting its focus to crypto. The community is discussing the low float, potential for a squeeze, and comparing it to other recent runners. Some traders are also noting the company's planned name change to AVAX One.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amidst significant price movement and high trading volume, sparking discussions about its valuation and potential for further gains. Community members are debating comparisons to Nvidia ($NVDA) and the impact of potential government actions related to quantum computing. Some traders are expressing caution, citing concerns about overvaluation and the possibility of a pullback, while others remain bullish, pointing to the company's technological advancements and potential for acquisitions.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending as investors react to Mike Alfred's appointment to the board, viewing it as a potential catalyst for growth and increased exposure within the fintech and crypto sectors. The community is actively debating whether this will lead to a significant turnaround for the company, with some expressing optimism and others remaining skeptical. Broader discussions include the company's strategic direction in digital assets and AI, particularly in the context of evolving crypto regulations.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as the stock approaches multi-year lows, sparking debates about whether it's a value trap or a buying opportunity. Community discussions revolve around a mini-tender offer from TRC Capital and the potential for a bounce after the offer expires, while some express concerns about declining sales and foot traffic. Despite the pessimism, some bulls cite the attractive dividend yield and potential for a turnaround, pointing to Taylor Swift's new album available at Target as a catalyst.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

Qualigen Therapeutics Inc

QLGN is trending due to a strategic $41 million investment from Faraday Future to pivot the company towards crypto and Web3, a move discussed by the community as a potential game-changer. Community chatter highlights the low float and potential for a squeeze, with some speculating on price targets. The stock's surge is attributed to this pivot and the potential it unlocks in the crypto space.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

BINI is trending due to a planned reverse stock split, its ninth since 2022, leading to concerns about value dilution and potential delisting. The community expresses frustration and accuses the company of being a scam, with many sharing stories of significant losses and criticizing management. Discussions also include the broader context of reverse splits and regulatory oversight.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending due to its acquisition of Metsera, a company focused on obesity drugs, for up to $7.3 billion, a move that signals PFE's renewed interest in the weight-loss market. Community discussion revolves around the potential impact of this acquisition on competitors like Viking Therapeutics and the broader implications for Pfizer's pipeline and future growth strategy within the competitive pharmaceutical landscape.

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Campbell, CA.

Semler Scientific Inc

Semler Scientific ($SMLR) is trending due to its acquisition by Strive ($ASST) in an all-stock deal, implying a significant premium. The community is actively discussing the arbitrage opportunity between the two stocks and the potential for gains based on the share exchange ratio. Some investors believe the market hasn't fully priced in the deal, while others are skeptical, citing the impact of Bitcoin's volatility on Strive's Bitcoin treasury strategy.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

MBX Biosciences Inc.

MBX Biosciences is trending following positive Phase 2 data for its hypoparathyroidism drug, with the community highlighting the potential for Phase 3 trials and analyst upgrades. Swing traders are also taking note of the major upside breakout and bullish signals, anticipating a continued uptrend. However, some traders remain cautious, pointing out the risks associated with pre-revenue biotech companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer Inc. (PFE) on Monday said that it will acquire biopharmaceutical company Metsera (MTSR) for $47.50 per share in cash at closing.The upfront purchase price of $47.50 per share represents a premium of 43% from Metsera’s closing share price on Friday. The deal represents a total enterprise value of approximately $4.9 billion for Metsera.Metsera shareholders will also receive a non-transferable contingent value right (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250922965053/en/Pfizer-to-Acquire-Metsera-and-its-Next-Generation-Obesity-Portfolio">expected</a> to close in the fourth quarter of 2025, subject to the satisfaction of customary closing conditions.Shares of Metsera soared 59% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MTSR">MTSR</a> jumped from ‘bullish’ to ‘extremely bullish' territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.New York City-based Metsera is a clinical-stage biopharmaceutical company developing medicines for obesity and cardiometabolic diseases.<a href="https://stocktwits.com/symbol/PFE">Pfizer</a> said on Monday that the proposed acquisition will add four highly differentiated clinical-stage programs to Pfizer’s pipeline, including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist, and MET-233i, a monthly amylin analog candidate, in addition to two other oral GLP-1 receptor agonists expected to begin clinical trials soon. GLP-1 receptor agonists are a class of medications that mimic the effects of the body's natural hormone glucagon-like peptide-1 (GLP-1) to treat type 2 diabetes and obesity. Amylin analogs, likewise, can lead to weight loss.“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,” said Pfizer CEO Albert Bourla. Pfizer scrapped its own obesity drug candidate, Danuglipron, earlier this year.The Financial Times had on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-metsera-7b-buyout-obesity-drug-race-lilly-novo/chDQXfYR3c9">reported</a> that the two companies could announce a deal as early as Monday.While Pfizer’s stock has declined 9% so far in 2025, Metsera’s stock has risen 25.7% over the same period.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micron-stock-gets-a-price-target-hike-from-stifel/chDQNFpR3cz">Micron Stock Gets A Price Target Hike From Stifel Ahead Of Q4 Earnings – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.

Equity

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.


Pfizer is reportedly preparing to buy weight-loss biotech Metsera in a deal that could be worth as much as $7.3 billion.The New York-based drugmaker would apparently pay $47.50 a share upfront and another $22.50 tied to milestones, a sharp premium to Metsera’s recent price of $33.32. An announcement could come as early as Monday, barring last-minute delays, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/aee4a71c-7ad6-4cde-852f-720a97542fac">report</a>,&nbsp;which cited two people familiar with the matter.The move comes after Pfizer scrapped its own obesity drug candidate, danuglipron, earlier this year. Metsera, which is listed in one of 2025’s biggest biotech IPOs, has drawn interest across the sector with MET-097i, a GLP-1 therapy that produced 11.3% weight loss over 12 weeks in a mid-stage trial.&nbsp;The company is also developing a monthly version of the shot, an amylin-based treatment aimed at avoiding muscle loss, and an oral pill. Pfizer shares, now worth about half their 2021 pandemic peak, closed Friday at $24, valuing the company at $136 billion.&nbsp;CEO Albert Bourla has been under pressure to reignite growth, with Pfizer’s last major deal being the $43 billion purchase of cancer drugmaker Seagen in 2023. A Metsera acquisition would put it in direct competition with Eli Lilly and Novo Nordisk, whose blockbuster GLP-1 drugs Zepbound and Wegovy are expanding into pill form.On Stocktwits, retail sentiment for both Pfizer and Metsera was ‘bullish’, with message volume ‘normal’ for Pfizer and ‘high’ for Metsera.One user&nbsp;labeled the reported deal value&nbsp;a “lousy premium” to Metsera’s recent trading levels and argued the company’s management may be selling too cheaply. The user added that Pfizer may have avoided a bigger gamble on Viking Therapeutics ahead of late-stage trials.<stembedurl>https://stocktwits.com/biolover/message/629465706</stembedurl>Another bullish user said that the acquisition could ultimately be seen as an $80-per-share buyout opportunity.<stembedurl>https://stocktwits.com/vu_jade/message/629466433</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> has declined 4.6% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> has risen 25.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up

Pfizer is pushing into the booming weight-loss market after its own drug setback, as rivals Eli Lilly and Novo Nordisk lead the field.

PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?

AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.

Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?

CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.

MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response

Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.

U.S. stocks experienced a modest pullback from their record highs as a strong August retail sales report tempered hopes of a bigger cut by the Federal Reserve at the September rate-setting meeting.Most experts and market watchers expect the central bank, led by Chair Jerome Powell, to cut rates by 25 basis points to 4-4.25%, with a section of them bracing for a “Sell the news” move.&nbsp; Former JPMorgan strategist Marko Kolanovic warned of a potential spike in volatility. In a post on X, he&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/markoinny/status/1968126762883383583">said</a>, “Systematic investors are maxed out. Potentially an explosive situation (like this April) when volatility increases.”Ahead of the crucial Fed meeting, the following stocks saw increased trading volume in Tuesday’s extended trading session.Nvidia Corp. (NVDA)After-hours move: +0.15%Trading volume: 7.6 millionNvidia’s stock fell for a second straight session on Tuesday, dragged by another negative China headline. The stock ended the session down 1.61% after a Reuters report, citing two people, said the company’s new artificial intelligence (AI) inference chip, the RTX6000D, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-s-china-focused-ai-chip-reportedly-struggles-to-win-big-buyers/chwyfEWRdyp">poor uptake&nbsp;</a>in the country.The&nbsp;<a href="https://stocktwits.com/symbol/NVDA">Nvidia stock</a> continued to elicit ‘bearish’ sentiment (43/100) from among the retail users of Stocktwits, and the message volume also stayed at ‘low’ levels.The stock has gained 30% year-to-date (YTD).Pfizer, Inc. (PFE)After-hours move: +0.17%Trading volume: 7.49 million<a href="https://stocktwits.com/symbol/PFE">Pfizer shares,</a> which are down 5% YTD, came on investors’ radar amid the oversold levels of the stock. Health and Human Services Secretary Robert Kennedy Jr.’s stance on vaccines and the resultant divisions within the department have also shifted the focus on vaccine developers, including Pfizer.Retail sentiment toward the stock stayed ‘bullish’ (61/100) and the message volume remained at ‘high’ levels.New Fortress Energy LLC (NFE)After-hours move: +35.49%Trading volume: 27.92 million<a href="https://stocktwits.com/symbol/NFE">New Fortress Energy stock</a> surged higher in the after-hours&nbsp;following a 45%&nbsp;jump in regular trading. The after-hours surge came after the company struck a long-term liquefied natural gas (LNG) <a href="https://stocktwits.com/news-articles/markets/equity/new-fortress-energy-stock-surges-on-4-b-puerto-rico-deal-lng-supply-deal/chDGfqMRdCJ">supply contract </a>with Puerto Rico.&nbsp;"Matching our LNG production with long-term offtake has always been our goal. This locks in sustainable long-term margins for NFE and provides a foundation of financial stability for our company," said Chris Guinta, CFO of New Fortress Energy.The New York-based integrated gas-to-power company has lost about 87% of its valuation this year due to investor worries concerning its debt, even as project delays weigh down. The strength seen in the stock is due to hopes that the company would reach a deal to restructure its debt.Retail sentiment toward the stock has improved to ‘extremely bullish’ (93/100) by late Tuesday, from ‘bullish’ a day ago, and the message volume rose to ‘extremely high’ levels.Tesla, Inc. (TSLA)After-hours move: +0.29%Trading volume: 4.33 millionTesla stock outperformed the broader market on Tuesday as it climbed 2.77% despite the S&amp;P 500’s modest pullback. The stock is steadily moving toward its highest level this year, thanks to a few catalysts, including CEO Elon Musk buying $1 billion worth of shares, the billionaire renewing his commitment toward the electric-vehicle business, optimism over the robotaxi opportunity, and expectations of delivery outperformance in the third quarter.The stock is still trading way off its all-time high of $488.54.On Stocktwits, retail traders stayed ‘extremely bullish’ (91/100) toward the&nbsp;<a href="https://stocktwits.com/symbol/TSLA">Tesla stock</a>, and the message volume continued to be ‘extremely high.’Tesla’s stock is up 4.40% for the year.Alphabet, Inc. (GOOGL) (GOOG)After-hours move: +0.04%Trading volume: 4.16 millionAlphabet, which is the newest $3 trillion club member, saw its shares retreat modestly on Tuesday.&nbsp;<a href="https://stocktwits.com/symbol/GOOG">Alphabet’s Class C stock</a> is up 32.45% this year. Sentiment toward the stock, however, remained ‘bearish’ (42/100), and the message volume dropped to ‘normal’ levels.Alphabet announced a $5 billion AI investment, while it faces a lawsuit from sell-side advertising company Magnite (MGNI), with the latter seeking financial damages and remedies following the U.S. District Court for the Eastern District of Virginia’s April ruling which found Google “willfully engaged in a series of anticompetitive acts to acquire and maintain monopoly power" in the ad exchange and ad server markets.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-stock-edges-up-after-hours-another-ai-heavyweight-jumps-aboard/chDGB18RdC5">Paramount Skydance Stock Edges Up After-Hours: Another AI Heavyweight Jumps Aboard While WBD Merger Talk Swirls</a>

Traders work on the floor of the New York Stock Exchange during afternoon trading on August 01, 2025 in New York City. (Photo by Michael M. Santiago/Getty Images)

Nvidia, Pfizer, New Fortress Energy, Tesla, Alphabet: What Sparked Heavy After-Hours Trading In These 5 Stocks?

 Nvidia stayed on investors’ radar amid the stock price volatility, while a contract win buoyed sentiment toward the beaten-down stock of LNG company New Fortress Energy.

MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer

Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.

Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?

CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know  

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$24.66
Prev Close	$24.03
Open	$24.30
Dividend Yield	6.37%
50-Day Moving Average	$24.66
Beta	0.44
Avg. Volume	43.39M
PE Ratio	12.78

52-Week High	$30.43
52-Week Low	$20.92
Market Capitalization	$136.62B
EPS (Annual)	$1.41
Price to Book	1.54
Revenue Per Employee	$785,518.52
Enterprise Value/EBITDA	N/A

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News

PFE Pfizer Inc